Press

The latest news about enGene's progress

The latest news

enGene announces poster presentation containing interim Phase 1 clinical trial data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium

Feb 14, 2023

Interim Phase 1 results from enGene's Phase 1/2 LEGEND study of intravesical EG-70 (detalimogene voraplasmid) demonstrate a 71% CR rate at three months in patients with high-grade non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) that is BCG-unresponsive.

enGene Appoints Alex Nichols, PhD as President and Chief Operating Officer

Feb 02, 2023

enGene, Inc. today announced that Alex Nichols, PhD, has joined the company as President and Chief Operating Officer.

enGene Appoints James C. Sullivan, PhD as Chief Scientific Officer

Mar 17, 2022

enGene Inc. today announced the appointment of James C. Sullivan, PhD, as its Chief Scientific Officer (CSO). In his role as CSO, Dr. Sullivan will lead research and development efforts that focus on new ways to expand the use of the company's gene therapy platform and assets.

Past News

enGene Announces positive preliminary phase 1/2 data with eg-70 in BCG-unresponsive non-muscle invasive bladder cancer

enGene Inc., a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues enabled by it proprietary DDX platform, today announced positive results from its LEGEND study, a first-in-human Phase 1/2 clinical trial of EG-70 for the treatment of high-grade Non-Muscle Invasive Bladder Cancer (NMIBC) in patients with carcinoma in situ (CIS) that are BCG-unresponsive.

enGene announces a poster presentation at the Society of Urologic Oncology Annual Meeting 2021

enGene Inc., a clinical-stage biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, today announced a poster presentation at the upcoming Society of Urologic Oncology Annual Meeting being held from December 1 to December 3, 2021.

enGene Announces First-in-Human dosing of eg-70 for the treatment of non-muscle invasive bladder cancer in phase 1/2 clinical trial

enGene Inc., a clinical-stage biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enable by its proprietary DDX platform, today announced the dosing of the first patient in the LEGEND study, a first in human Phase 1/2 clinical trial of EG-70 in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

Contact